Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -9.10% is 57% above its 5-year average of -21.22%, near the high end of its 5-year range (-64.24%–-2.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.70% below its 12-month average of -7.60%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -9.10%.
RETURN ON EQUITY (ROE)
-9.10%
RETURN ON EQUITY (ROE) AVG TTM
-7.60%
RETURN ON EQUITY (ROE) AVG 3Y
-20.55%
RETURN ON EQUITY (ROE) AVG 5Y
-21.22%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.70%
CURRENT VS 3Y AVG
+55.73%
CURRENT VS 5Y AVG
+57.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+78.34%
vs the sector median at left
10x Genomics, Inc.
Market Cap
$10.20B
Return on Equity (ROE)
-9.10%
TTM Avg
-7.60%
3Y Avg
-20.55%
5Y Avg
-21.22%
Market Cap
$10.21B
Return on Equity (ROE)
-0.17%
TTM Avg
18.91%
3Y Avg
22.60%
5Y Avg
24.60%
Market Cap
$10.14B
Return on Equity (ROE)
9.77%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
Market Cap
$10.12B
Return on Equity (ROE)
N/A
TTM Avg
77.45%
3Y Avg
86.84%
5Y Avg
112.62%
Market Cap
$10.30B
Return on Equity (ROE)
11.23%
TTM Avg
7.12%
3Y Avg
6.90%
5Y Avg
7.16%
Market Cap
$10.03B
Return on Equity (ROE)
15.51%
TTM Avg
15.81%
3Y Avg
15.92%
5Y Avg
17.27%
Market Cap
$10.39B
Return on Equity (ROE)
-30.67%
TTM Avg
-30.29%
3Y Avg
-30.25%
5Y Avg
-31.47%
Market Cap
$9.93B
Return on Equity (ROE)
3.10%
TTM Avg
-8.94%
3Y Avg
-15.72%
5Y Avg
1.14%
Market Cap
$9.89B
Return on Equity (ROE)
1.97%
TTM Avg
0.51%
3Y Avg
3.14%
5Y Avg
3.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 10x Genomics, Inc. (TXG) | $10.20B | -9.10% | -7.60% | -20.55% | -21.22% |
| Molina Healthcare, Inc. (MOH)vs › | $10.21B | -0.17% | 18.91% | 22.60% | 24.60% |
| Align Technology, Inc. (ALGN)vs › | $10.14B | 9.77% | 10.54% | 10.84% | 19.93% |
| ImmunityBio, Inc. (IBRX)vs › | $10.12B | N/A | 77.45% | 86.84% | 112.62% |
| Globus Medical, Inc. (GMED)vs › | $10.30B | 11.23% | 7.12% | 6.90% | 7.16% |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 15.51% | 15.81% | 15.92% | 17.27% |
| Twist Bioscience Corporation (TWST)vs › | $10.39B | -30.67% | -30.29% | -30.25% | -31.47% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 3.10% | -8.94% | -15.72% | 1.14% |
| Repligen Corporation (RGEN)vs › | $9.89B | 1.97% | 0.51% | 3.14% | 3.97% |
| Universal Health Services, Inc. (UHS)vs › | $10.70B | 20.31% | 18.80% | 15.17% | 15.31% |
ROE
-9.1%
ROA
-7.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -9.10% |
| 2026-03-31 | -2.78% |
| 2025-12-31 | -5.47% |
| 2025-09-30 | -9.72% |
| 2025-06-30 | -10.94% |
| 2025-03-31 | -22.21% |
| 2024-12-31 | -25.72% |
| 2024-09-30 | -25.26% |
| 2024-06-30 | -33.12% |
| 2024-03-31 | -36.77% |
| 2023-12-31 | -34.42% |
| 2023-09-30 | -29.97% |
| 2023-06-30 | -21.72% |
| 2023-03-31 | -21.73% |
| 2022-12-31 | -20.60% |
| 2022-09-30 | -21.56% |
| 2022-06-30 | -18.19% |
| 2022-03-31 | -11.04% |
| 2021-12-31 | -7.12% |
| 2021-09-30 | -56.90% |
| 2021-06-30 | -64.24% |
| 2021-03-31 | -70.85% |
| 2020-12-31 | -73.43% |
| 2020-09-30 | -16.28% |
| 2020-06-30 | -19.95% |
| 2020-03-31 | -11.92% |
| 2019-12-31 | -7.44% |
| 2019-09-30 | -23.64% |
| 2019-06-30 | -688.96% |
| 2019-03-31 | -431.82% |
